INTRODUCTION: Approximately 23% of melanoma patients will eventually develop pulmonary metastases and have a median survival of only about 7-11 months. Because pulmonary metastasectomy can improve this statistic, we investigated clinicopathologic features and biological correlates that might be used to identify surgical candidates. METHODS: Archived operative specimens and clinical records were retrieved for 20 melanoma patients who underwent resection of isolated pulmonary metastases at the John Wayne Cancer Institute, Saint John's Health Center. Five-year postmetastasectomy survival (PMS) rate was correlated with age, number of pulmonary metastases, tumor doubling time (TDT), tumor necrosis, and immunohistochemical expressions of four biological markers: Ki-67, glucose transporter-1 (Glut-1), caspase-3, and CD31. RESULTS: Median TDT was 61 days. On multivariate analysis, TDT (P = 0.008), Glut-1 intensity (P = 0.04), and CD31 expression (P = 0.004) were the significant predictors of PMS. Age, number of pulmonary metastases, tumor necrosis, and expression of Ki-67 or caspase-3 did not significantly impact survival. Median TDT was 56 days with Glut-1 expression versus 165 days without Glut-1 expression (P = 0.002), and Glut-1 staining intensity independently affected TDT (P = 0.012). CONCLUSIONS: Surgical resection may be preferable to toxic systemic therapies in melanoma patients whose isolated pulmonary metastases have a long TDT (> or = 61 days) and no biopsy evidence of Glut-1 expression.
INTRODUCTION: Approximately 23% of melanomapatients will eventually develop pulmonary metastases and have a median survival of only about 7-11 months. Because pulmonary metastasectomy can improve this statistic, we investigated clinicopathologic features and biological correlates that might be used to identify surgical candidates. METHODS: Archived operative specimens and clinical records were retrieved for 20 melanomapatients who underwent resection of isolated pulmonary metastases at the John Wayne Cancer Institute, Saint John's Health Center. Five-year postmetastasectomy survival (PMS) rate was correlated with age, number of pulmonary metastases, tumor doubling time (TDT), tumor necrosis, and immunohistochemical expressions of four biological markers: Ki-67, glucose transporter-1 (Glut-1), caspase-3, and CD31. RESULTS: Median TDT was 61 days. On multivariate analysis, TDT (P = 0.008), Glut-1 intensity (P = 0.04), and CD31 expression (P = 0.004) were the significant predictors of PMS. Age, number of pulmonary metastases, tumor necrosis, and expression of Ki-67 or caspase-3 did not significantly impact survival. Median TDT was 56 days with Glut-1 expression versus 165 days without Glut-1 expression (P = 0.002), and Glut-1 staining intensity independently affected TDT (P = 0.012). CONCLUSIONS: Surgical resection may be preferable to toxic systemic therapies in melanomapatients whose isolated pulmonary metastases have a long TDT (> or = 61 days) and no biopsy evidence of Glut-1 expression.
Authors: S Kothakota; T Azuma; C Reinhard; A Klippel; J Tang; K Chu; T J McGarry; M W Kirschner; K Koths; D J Kwiatkowski; L T Williams Journal: Science Date: 1997-10-10 Impact factor: 47.728
Authors: Rebecca P Petersen; Steven I Hanish; John C Haney; Charles C Miller; William R Burfeind; Douglas S Tyler; Hilliard F Seigler; Walter Wolfe; Thomas A D'Amico; David H Harpole Journal: J Thorac Cardiovasc Surg Date: 2007-01 Impact factor: 5.209
Authors: C M Balch; S J Soong; J E Gershenwald; J F Thompson; D S Reintgen; N Cascinelli; M Urist; K M McMasters; M I Ross; J M Kirkwood; M B Atkins; J A Thompson; D G Coit; D Byrd; R Desmond; Y Zhang; P Y Liu; G H Lyman; A Morabito Journal: J Clin Oncol Date: 2001-08-15 Impact factor: 44.544
Authors: Eddy C Hsueh; Richard Essner; Leland J Foshag; David W Ollila; Guy Gammon; Steven J O'Day; Peter D Boasberg; Stacey L Stern; Xing Ye; Donald L Morton Journal: J Clin Oncol Date: 2002-12-01 Impact factor: 44.544
Authors: H Minn; M Lapela; P J Klemi; R Grénman; S Leskinen; P Lindholm; J Bergman; E Eronen; M Haaparanta; H Joensuu Journal: J Nucl Med Date: 1997-12 Impact factor: 10.057
Authors: A Slominski; T-K Kim; A A Brożyna; Z Janjetovic; D L P Brooks; L P Schwab; C Skobowiat; W Jóźwicki; T N Seagroves Journal: Arch Biochem Biophys Date: 2014-07-02 Impact factor: 4.013
Authors: Nikolaus B Wagner; Max M Lenders; Kathrin Kühl; Lydia Reinhardt; Fiona André; Milena Dudda; Natalie Ring; Chiara Ebel; Ramon Stäger; Caroline Zellweger; Roland Lang; Michael Paar; Philipp Gussek; Georg Richtig; Suzan H Stürmer; Susanne Kimeswenger; Angela Oellinger; Andrea Forschner; Ulrike Leiter; Benjamin Weide; Maximilian Gassenmaier; Amadeus Schraag; Bernhard Klumpp; Wolfram Hoetzenecker; Carola Berking; Erika Richtig; Mirjana Ziemer; Johanna Mangana; Patrick Terheyden; Carmen Loquai; Van Anh Nguyen; Christoffer Gebhardt; Friedegund Meier; Stefan Diem; Antonio Cozzio; Lukas Flatz; Martin Röcken; Claus Garbe; Thomas K Eigentler Journal: J Immunother Cancer Date: 2021-05 Impact factor: 13.751
Authors: Andreas Koch; Sven Arke Lang; Peter Johannes Wild; Susanne Gantner; Abdo Mahli; Gerrit Spanier; Mark Berneburg; Martina Müller; Anja Katrin Bosserhoff; Claus Hellerbrand Journal: Oncotarget Date: 2015-10-20
Authors: Noelia A Massari; Melisa B Nicoud; Lorena Sambuco; Graciela P Cricco; Diego J Martinel Lamas; María V Herrero Ducloux; Horacio Blanco; Elena S Rivera; Vanina A Medina Journal: Oncotarget Date: 2017-04-18